Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04554381
Status:
UNKNOWN
Last Update Posted:
2020-09-18
First Post:
2020-09-14
Brief Title:
Assesment of JL1 Expression in Acute Leukemia
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Assesment of JL1 Expression in B-cell Acute Lymphoblastic Leukemia
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to assess JL1 expression by flow cytometric immunophenotyping in patients with B-cell Acute Lymphoblastic Leukemia ALL and to correlate it with clinical morphological immunophenotypic cytogenetic data and response to treatment
Detailed Description:
Acute Lymphoblastic Leukemia ALL is characterized by a rapidly progressive disease It accounts for approximately 75 of all cases of childhood leukemias that produces large and immature cells 20 or more lymphoblasts in the bone marrow BM andor the blood that cant carry out their normal BM function Terwilliger and Abdul-Hay 2017
The main cause of ALL lies in the genetic or acquired injury to DNA of a single cell in the BM with the presence of risk factors such as radiation benzene exposure Down syndrome and past treatment with chemotherapeutic agents which leads to uncontrolled and exaggerated growth and accumulation of lymphoblasts which fail to function as normal blood cells This results in blocking the production of normal blood cells and leads to anemia thrombocytopenia and neutropenia The most frequent signs are lymphadenopathies hepatosplenomegaly fever anemia signs of hemorrhage and bone tenderness
The prognostic factors of ALL include patients factors such as age white blood cell WBC count and genetic factors such as chromosome and gene changes along with the immunophenotypic characteristics of the leukemic blast cells and the individual response to therapy
JL1 is a CD43 epitope and mucin family cell surface glycoprotein that is expressed on leukemic cells It is expressed on hematopoietic cells at different stages of differentiation including early stage lymphoid precursors and late stage of myeloid cells Expression patterns of JL1 antigen occurs on cell surface of leukemic cells BM cells and phytohemagglutinin PHA-activated lymphocytes Most leukemic cells usually express JL1 even in weak positive cases
JL1 is usually expressed in about 60 of acute leukemia regardless of the lineage It was also detected on CD34 CD10 lymphoid precursors and some immature myeloid cells in BM An anti-JL1 a monoclonal antibody that is selectively reactive with antigen in spite of the differences in the molecular weight is mixed with a toxic substance that target the leukemic cells which leads to the emergence of its role as a therapeutic agent
Therefore the invistigators aim to study JL1 expression on leukemic cells in ALL patients in South Egypt Cancer Institute as we hypothesis that it can be used as an adjunctive marker for the initial diagnosis and the follow up of ALL
The main cause of ALL lies in the genetic or acquired injury to DNA of a single cell in the BM with the presence of risk factors such as radiation benzene exposure Down syndrome and past treatment with chemotherapeutic agents which leads to uncontrolled and exaggerated growth and accumulation of lymphoblasts which fail to function as normal blood cells This results in blocking the production of normal blood cells and leads to anemia thrombocytopenia and neutropenia The most frequent signs are lymphadenopathies hepatosplenomegaly fever anemia signs of hemorrhage and bone tenderness
The prognostic factors of ALL include patients factors such as age white blood cell WBC count and genetic factors such as chromosome and gene changes along with the immunophenotypic characteristics of the leukemic blast cells and the individual response to therapy
JL1 is a CD43 epitope and mucin family cell surface glycoprotein that is expressed on leukemic cells It is expressed on hematopoietic cells at different stages of differentiation including early stage lymphoid precursors and late stage of myeloid cells Expression patterns of JL1 antigen occurs on cell surface of leukemic cells BM cells and phytohemagglutinin PHA-activated lymphocytes Most leukemic cells usually express JL1 even in weak positive cases
JL1 is usually expressed in about 60 of acute leukemia regardless of the lineage It was also detected on CD34 CD10 lymphoid precursors and some immature myeloid cells in BM An anti-JL1 a monoclonal antibody that is selectively reactive with antigen in spite of the differences in the molecular weight is mixed with a toxic substance that target the leukemic cells which leads to the emergence of its role as a therapeutic agent
Therefore the invistigators aim to study JL1 expression on leukemic cells in ALL patients in South Egypt Cancer Institute as we hypothesis that it can be used as an adjunctive marker for the initial diagnosis and the follow up of ALL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None